Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe.
Young AM, Stoner MCD, Mathebula F, Mohuba R, Baez A, Seyama L, Mutero P, Etima J, Fabiano Z, Fairlie L, Mayo AJ, Balkus JE, Song M, Bunge K, Piper J, Balan IC, van der Straten A, Montgomery ET. Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe. AIDS Behav 2024 Jul 25. Epub ahead of print.
Perception of couples' on multipurpose prevention technology attribute choice: the case of MTN 045.
Dandadzi A, Young AM, Musara P, Shapley-Quinn MK, Kemigisha D, Mutero P, Mgodi NM, Etima J, Minnis AA. Perception of couples' on multipurpose prevention technology attribute choice: the case of MTN 045. BMC Public Health 2024 Jul 15;24(1):1876. PMCID: PMC11247780
Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial.
Ngure K, Browne EN, Reddy K, Friedland BA, van der Straten A, Palanee-Phillips T, Nakalega R, Gati B, Kalule HN, Siziba B, Soto-Torres L, Nair G, Garcia M, Celum C, Roberts ST. Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial. AIDS Behav 2024 Jun 9. Epub ahead of print
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings.
Achilles SL, Kelly CW, Hoesley CJ, Blithe DL, Brown J, Richardson BA, Devlin B, Hendrix CW, Poloyac SM, Marzinke MA, Gundacker H, Singh D, Piper JM, Johnson S, Steytler J, Chen BA; MTN-030/IPM 041 and MTN-044/IPM 053/CCN019 Protocol Teams for the Microbicide Trials Network and the Contraceptive Clinical Trials Network. Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings. PLoS One 2024 Jun 5;19(6):e0304552.
History of Rectal Product Use and Country of Residence Influence Preference for Rectal Microbicide Dosage Forms Among Young Sexual and Gender Minorities: A Multi-country Trial Comparing Placebo Douche, Suppository, and Insert Products.
Giguere R, Balán IC, Kutner BA, Choi SK, Tingler R, Johnson S, Macagna N, Webster J, Liu A, Chariyalertsak S, Hoesley C, Gonzales P, Ho K, Kayange N, Palanee-Phillips T, Brown E, Zemanek J, Jacobson CE, Doncel GF, Piper J, Bauermeister JA; MTN-035 Protocol Team. History of Rectal Product Use and Country of Residence Influence Preference for Rectal Microbicide Dosage Forms Among Young Sexual and Gender Minorities: A Multi-country Trial Comparing Placebo Douche, Suppository, and Insert Products. AIDS Behav 2024 May 13. Epub ahead of print
Mutero P, Young AM, Ryan JH, Reddy K, Kemigisha D, Gondwe D, Dandadzi A, Musara P. Community beliefs and practices during pregnancy and their potential effect on HIV prevention product use in Sub Saharan Africa. African J AIDS HIV Res 2024; 12 (5):1-10.
A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
Riddler SA, Kelly CW, Hoesley CJ, Ho KS, Piper JM, Edick S, Heard F, Doncel GF, Johnson S, Anderson PL, Brand RM, Kunjara Na Ayudhya RP, Bauermeister JA, Hillier SL, Hendrix CW. A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention. J Infect Dis 2024 Apr 24:jiae211. doi: 10.1093/infdis/jiae211. Epub ahead of print
Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women using the Dapivirine Vaginal Ring.
Stalter RM, Dong TQ, Hendrix CW, Palanee-Phillips T, van der Straten A, Hillier SL, Kiweewa FM, Mgodi NM, Marzinke MA, Bekker LG, Soto-Torres L, Baeten JM, Brown ER; MTN-020/ASPIRE Study Team. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women using the Dapivirine Vaginal Ring. J Infect Dis 2024 Apr 12;229(4):1158-1165. PMCID: PMC11011174
Depression Among Pregnant and Breastfeeding Persons Participating in Two Randomized Trials of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis (PrEP) in Malawi, South Africa, Uganda, and Zimbabwe.
Stoner MCD, Mathebula F, Sedze N, Seyama L, Mohuba R, Fabiano Z, Etima J, Young A, Scheckter R, van der Straten A, Piper J, Noguchi L, Montgomery ET, Balán IC. Depression Among Pregnant and Breastfeeding Persons Participating in Two Randomized Trials of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis (PrEP) in Malawi, South Africa, Uganda, and Zimbabwe. AIDS Behav 2024 Mar 25. Epub ahead of print
A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035.
Bauermeister J, Lin W, Tingler R, Liu A, Chariyalertsak S, Hoesley C, Gonzales P, Ho K, Kayange N, Phillips TP, Johnson S, Brown E, Zemanek J, Jacobson CE, Doncel GF, Piper J; MTN-035 Protocol Team for the Microbicide Trials Network. A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035. J Int AIDS Soc 2024 Mar;27(3):e26219. PMCID: PMC10945032
Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention.
Peet MM, Agrahari V, Clark MR, Doncel GF. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention. Pharmaceutics 2024; 16(3):348. PMCID: PMC10974834
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.
Liu AY, Gundacker H, Richardson B, Chen BA, Hoesley C, van der Straten A, Brown A, Beamer M, Robinson J, Jacobson CE, Scheckter R, Bunge K, Schwartz J, Thurman A, Piper JM, Marzinke MA; MTN-038 Protocol Team for the Microbicide Trials Network. Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States. J Int AIDS Soc 2024 Mar;27(3):e26223. PMCID: PMC10935712
Acceptability of the Dapivirine Vaginal Ring and Oral Truvada Among African Users in Late-Stage of Pregnancy.
Montgomery ET, Hawley I, Fairlie L, Bunge K, Mathebula F, Etima J, Mutero P, Senyama L, Mayo A, Stoner MCD, Piper J, Balan I, van der Straten A. Acceptability of the Dapivirine Vaginal Ring and Oral Truvada Among African Users in Late-Stage of Pregnancy. AIDS Behav 2024 Mar;28(3):963-973. PMCID: PMC10896786
DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.
Bunge K, Balkus JE, Fairlie L, Mayo AJ, Nakabiito C, Mgodi N, Gadama L, Matrimbira M, Chappell CA, Piper J, Chakhtoura N, Szydlo DW, Richardson B, Hillier SL. DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy. J Acquir Immune Defic Syndr 2024 Jan 1;95(1):65-73.
Brief Report: HIV Drug Resistance Assessment among Women who Seroconverted during the MTN-025/HOPE Open-Label Extension Dapivirine Vaginal Ring Trial.
Parikh UM, Penrose KJ, Heaps AL, Sethi R, Goetz BJ, Szydlo D, Chandran U, Palanee-Phillips T, Mgodi NM, Baeten JM, Mellors JW; and the MTN-025/HOPE Study Team. Brief Report: HIV Drug Resistance Assessment among Women who Seroconverted during the MTN-025/HOPE Open-Label Extension Dapivirine Vaginal Ring Trial. J Acquir Immune Defic Syndr 2024 Jan 1;95(1):35-41. PMCID: PMC11042691
Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex.
Browne EN, Torjesen K, Mirembe BG, Palanee-Phillips T, Jeenarain N, Chitukuta M, Stoner MCD, Mansoor LE, Reddy K, Tauya TT, Naidoo L, Siva S, Richardson B, Dadabhai S, Seyama L, Soto-Torres L, van der Straten A on behalf of the MTN-020/ASPIRE Study Team. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex. AIDS Care 2024 Jan;36(1):80-86. PMCID: PMC10579446
A latent trajectory analysis of young sexual and gender minorities' adherence to three rectal microbicide placebo formulations (MTN-035; a randomized crossover trial).
Choi SK, Bauermeister J, Tingler RC, Johnson S, Macagna N, Ho K, Hoesley C, Liu A, Kayange N, Palanee-Phillips T, Chariyalertsak S, Gonzales P, Piper JM; MTN-035 Protocol Team. A latent trajectory analysis of young sexual and gender minorities' adherence to three rectal microbicide placebo formulations (MTN-035; a randomized crossover trial). BMC Public Health 2023 Dec 8;23(1):2464. PMCID: PMC10709877.
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G, Celum C, Szydlo D, Brown ER, Akello CA, Nakalega R, Macdonald P, Milan G, Palanee-Phillips T, Reddy K, Tahuringana E, Muhlanga F, Nakabiito C, Bekker LG, Siziba B, Hillier SL, Baeten JM, Garcia M, Johnson S, McClure T, Levy L, Livant E, Jacobson C, Soto-Torres L, van der Straten A, Hosek S, Rooney JF, Steytler J, Bunge K, Parikh U, Hendrix C, Anderson P, Ngure K; REACH Protocol Team. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Lancet HIV 2023 Dec;10(12):e779-e789. PMCID: PMC10756058
Acceptability and Use of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) During Breastfeeding in South Africa, Malawi, Zimbabwe, and Uganda.
Stoner MCD, Hawley I, Mathebula F, Horne E, Etima J, Kemigisha D, Mutero P, Dandadzi A, Seyama L, Fabiano Z, Scheckter R, Noguchi L, Owor M, Balkus JE, Montgomery ET. Acceptability and Use of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) During Breastfeeding in South Africa, Malawi, Zimbabwe, and Uganda. AIDS Behav 2023 Dec;27(12):4114-4123. PMCID: PMC10615878
Adolescent Girls and Young Women's Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis.
Young AM, Mancuso N, Atujuna M, Tenza S, Chitukuta M, Kemigisha D, Ngure K, van der Straten A, Garcia M, Szydlo D, Soto-Torres L, Roberts ST. Adolescent Girls and Young Women's Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis. AIDS Behav 2023 Dec;27(12):3941-3951. PMCID: PMC10598125
The Association Between Heterosexual anal Intercourse and HIV Acquisition in Three Prospective Cohorts of Women.
Silhol R, Nordsletten A, Maheu-Giroux M, Elmes J, Staunton R, Owen B, Shacklett B, McGowan I, Feliciano KG, van der Straten A, Eller LA, Robb M, Marrazzo J, Dimitrov D, Boily MC. The Association Between Heterosexual anal Intercourse and HIV Acquisition in Three Prospective Cohorts of Women. AIDS Behav 2023 Dec;27(12):4010-4021. PMCID: PMC10598156
How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis.
Roberts ST, Mancuso N, Williams K, Nabunya HK, Mposula H, Mugocha C, Mvinjelwa P, Garcia M, Szydlo DW, Soto-Torres L, Ngure K, Hosek S. How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis. J Int AIDS Soc 2023 Nov;26(11):e26189. PMCID: PMC10630658
The impact of COVID-19 on sexual behavior, HIV prevention interest, general healthcare access, and other HIV risk factors among trial participants in Malawi, South Africa, Uganda, and Zimbabwe.
Mancuso N, Mathebula F, Chitukuta M, Matambanadzo KV, Tenza S, Reddy K, Nobula L, Kemigisha D, Stoner MCD. The impact of COVID-19 on sexual behavior, HIV prevention interest, general healthcare access, and other HIV risk factors among trial participants in Malawi, South Africa, Uganda, and Zimbabwe. Front Reprod Health 2023 Oct 30;5:1270419. PMCID: PMC10642282
Women's motivations for participating in the dapivirine vaginal ring open label extension study.
Naidoo K, Montgomery ET, Katz AWK, Garcia M, Naidoo S, Mansoor LE. Women's motivations for participating in the dapivirine vaginal ring open label extension study. AIDS Care 2023 Sep 21:1-17.
Participant experiences with a multipurpose vaginal ring for HIV and pregnancy prevention during a phase 1 clinical trial: learning from users to improve acceptability.
Shapley-Quinn MK, Song M, Chen BA, Devlin B, Luecke E, Brown J, Blithe DL, Achilles SL and van der Straten A. Participant experiences with a multipurpose vaginal ring for HIV and pregnancy prevention during a phase 1 clinical trial: learning from users to improve acceptability. Front Reprod Health 2023 Jul 6;5:1147628. PMCID: PMC10359149
Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study).
Ngure K, Friedland BA, Szydlo DW, Roberts ST, Garcia M, Levy L, Akello CA, Reddy K, Palanee-Phillips T, Macdonald P, Siziba B, Soto-Torres L, Hosek S, Hillier SL, Nair G, Celum C, van der Straten A. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study). PLoS One 2023 Jun 23;18(6):e0287525. PMCID: PMC10289422.
A randomized trial of safety, acceptability and adherence of three rectal microbicide placebo formulations among young sexual and gender minorities who engage in receptive anal intercourse (MTN-035).
Bauermeister JA, Dominguez Islas C, Jiao Y, Tingler R, Brown E, Zemanek J, Giguere R, Balan I, Johnson S, Macagna N, Lucas J, Rose M, Jacobson C, Collins C, Livant E, Singh D, Ho K, Hoesley C, Liu A, Kayange N, Palanee-Phillips T, Chariyalertsak S, Gonzales P, Piper J; MTN-035 Protocol Team. A randomized trial of safety, acceptability and adherence of three rectal microbicide placebo formulations among young sexual and gender minorities who engage in receptive anal intercourse (MTN-035). PLoS One 2023 Apr 12;18(4):e0284339. PMCID: PMC10096248
Integrating Gender-Based Violence Screening and Support into the Research Clinic Setting: Experiences from an HIV Prevention Open-Label Extension Trial in Sub-Saharan Africa.
Garcia M, Roberts ST, Mayo AJ, Scheckter R, Mansoor LE, Palanee-Phillips T, Reddy K, Naidoo Y, Akello CA, Gaffoor Z, Siva S, Rushwaya C, Hlahla K, Jambaya J, Makoni R, Kachale E, Ndovie M, Zuma J, Montgomery ET; MTN-025/HOPE study team. Integrating Gender-Based Violence Screening and Support into the Research Clinic Setting: Experiences from an HIV Prevention Open-Label Extension Trial in Sub-Saharan Africa. AIDS Behav 2023 Apr;27(4):1277-1286. PMCID: PMC10036410
Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial.
Mirembe BG, Cabrera MV, van der Straten A, Nakalega R, Cobbing M, Mgodi NM, Palanee-Phillips T, Mayo AJ, Dadabhai S, Mansoor LE, Siva S, Nair G, Chinula L, Akello CA, Nakabiito C, Soto-Torres LE, Baeten JM, Brown ER. Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial. AIDS Behav 2023 Mar;27(3):1030-1043. PMCID: PMC10102709
Intimate Partner Violence and Engagement in the HIV Care Continuum among Women in Sub-Saharan Africa: A Prospective Cohort Study.
Roberts ST, van der Straten A, Rael CT, Gorbach PM, Palanee-Phillips T, Reddy K, Naidoo K, Dadabhai S, Chinula L, Gaffoor Z, Levy L, Balkus JE, Riddler SA. Intimate Partner Violence and Engagement in the HIV Care Continuum among Women in Sub-Saharan Africa: A Prospective Cohort Study. AIDS Behav 2023 Mar;27(3):984-989. Erratum in: AIDS Behav. 2022 Nov 8; PMCID: PMC10032576
Male partner opinions of the dapivirine vaginal ring used during an open-label extension HIV prevention trial in KwaZulu-Natal, South Africa.
Morar NS, Mansoor LE, Naidoo K, Katz AW, Garcia M, Duma C, Precious Myeni NB, Tshbalala T, Naidoo S, Montgomery ET. Male partner opinions of the dapivirine vaginal ring used during an open-label extension HIV prevention trial in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr 2023 Feb 1;92(2):127-133. PMCID: PMC9839591
Brief Report: Dapivirine ring HIV-1 prevention effectiveness for women engaged in vaginal and anal intercourse: insights from mathematical modeling.
Peebles K, Brown ER, Hendrix CW, Palanee-Phillips T, van der Straten A, Harkoo I, Reddy K, Mirembe BG, Jeenarain N, Hillier SL, Baeten JM, Barnabas RV; MTN-020/ASPIRE study team. Brief Report: Dapivirine ring HIV-1 prevention effectiveness for women engaged in vaginal and anal intercourse: insights from mathematical modeling. J Acquir Immune Defic Syndr 2023 Feb 1;92(2):122-126. PMCID: PMC9839478
Efficacy and Action of the Dapivirine Vaginal Ring as Understood by Women Participating in an Open Label Extension Study.
Naidoo K, Montgomery ET, Katz AW, Morgan G, Krishnaveni R, Lydia ST, Sarita N, Leila ME. Efficacy and Action of the Dapivirine Vaginal Ring as Understood by Women Participating in an Open Label Extension Study. AIDS Behav 2023 Jan;27(1):75-81.
Couples' decision making regarding the use of multipurpose prevention technology (MPT) for pregnancy and HIV prevention.
Stoner MCD, Browne EN, Etima J, Musara P, Hartmann M, Shapley-Quinn MK, Kemigisha D, Mutero P, Mgodi NM, Nakabiito C, Bhushan NL, Piper J, van der Straten A, Minnis AM. Couples' decision making regarding the use of multipurpose prevention technology (MPT) for pregnancy and HIV prevention. AIDS Behav 2023 Jan;27(1):198-207. PMCID: PMC9805468
Understanding the role of men in women's use of the vaginal ring and oral PrEP during pregnancy and breastfeeding: multi-stakeholder perspectives.
Musara P, Hartmann M, Ryan JH, Reddy K, Ggita J, Mutero P, Macagna N, Taulo F, Mgodi NM, Piper J, van der Straten A. Understanding the role of men in women's use of the vaginal ring and oral PrEP during pregnancy and breastfeeding: multi-stakeholder perspectives. Afr J AIDS Res 2022 Dec;21(4):354-363. PMCID: PMC9983781
Couples' Preferences for "2 in 1" Multipurpose Prevention Technologies to Prevent Both HIV and Pregnancy: Results of a Discrete Choice Experiment in Uganda and Zimbabwe.
Minnis AM, Etima J, Musara P, Browne EN, Mutero P, Kemigisha D, Mgodi NM, Nakabiito C, Shapley-Quinn MK, Stoner MCD, Hartmann M, Macagna N, Piper J, van der Straten A. Couples' Preferences for "2 in 1" Multipurpose Prevention Technologies to Prevent Both HIV and Pregnancy: Results of a Discrete Choice Experiment in Uganda and Zimbabwe. AIDS Behav 2022 Dec;26(12):3848-3861. PMCID: PMC9175528
MTN-033: a Phase 1 Study Comparing Applicator versus "as Lubricant" Delivery of Rectal Dapivirine Gel.
Ho K, Dominguez-Islas C, Szydlo D, Edick S, Macagna N, Riddler SA, Brand RM, Jacobson CE, Kramzer L, Kunjara Na Ayudhya RP, Piper J, Marzinke MA, Bauermeister J, Nuttall J, Hillier SL, Hendrix CW. MTN-033: a Phase 1 Study Comparing Applicator versus "as Lubricant" Delivery of Rectal Dapivirine Gel. Antimicrob Agents Chemother 2022 Nov 15;66(11):e0081622. PMCID: PMC9664840
Women's experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring.
Katz AWK, Balán IC, Reddy K, Etima J, Weber K, Tauya T, Atujuna M, Scheckter R, Ngure K, Soto-Torres L, Mgodi N, Palanee-Phillips T, Baeten JM, van der Straten A. Women's experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring. AIDS Behav 2022 Nov;26(11):3607-3619. PMCID: PMC9561023
Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative Findings on MPT Attribute Preferences from the CUPID Study (MTN-045).
Bhushan NL, Musara P, Hartmann M, Stoner MCD, Shah SR, Nabukeera J, Rukundo I, Mutero P, Lewis MA, Piper J, Shapley-Quinn MK, Etima J, Minnis AM. Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative Findings on MPT Attribute Preferences from the CUPID Study (MTN-045). J Int AIDS Soc 2022 Oct;25(10):e26024. PMCID: PMC9577116
Population-level correlation between incidence of curable sexually transmitted infections and HIV-1 among African women participating in HIV-1 pre-exposure prophylaxis trials.
Hunidzarira P, Brown ER, Chirenje ZM, Hillier SL, Marrazzo JM, Palanee-Phillips T, Kiweewa FM, Baeten JM; MTN-003/VOICE and MTN-020/ASPIRE Study Teams. Population-level correlation between incidence of curable sexually transmitted infections and HIV-1 among African women participating in HIV-1 pre-exposure prophylaxis trials. J Infect Dis 2022 Sep 21;226(6):1069-1074. PMCID: PMC10233491
''Ask the way from those who have walked it before"-Grandmothers' roles in health-related decision making and HIV pre-exposure prophylaxis use among pregnant and breastfeeding women in sub-Saharan Africa.
Reddy K, Kemigisha D, Chitukuta M, Dadabhai S, Mathebula F, Tenza S, Palanee-Phillips T, Ryan J, Macagna N, Musara P, van der Straten A. ''Ask the way from those who have walked it before"-Grandmothers' roles in health-related decision making and HIV pre-exposure prophylaxis use among pregnant and breastfeeding women in sub-Saharan Africa. PLoS One 2022 Sep 1;17(9):e0271684. PMCID: PMC9436035
Acceptability of PC-1005 Gel Administered Rectally to HIV-1 Seronegative Adults at Three Different Volume Levels (MTN-037).
Bauermeister JA, Tingler RC, Ho K, Scheckter R, McClure T, Davis J, Piper J, Friedland BA, Edick S, Song M, Jiao Y, Hendrix CW, Hoesley C. Acceptability of PC-1005 Gel Administered Rectally to HIV-1 Seronegative Adults at Three Different Volume Levels (MTN-037). AIDS Educ Prev. 2022 Aug;34(4):257-271. doi: 10.1521/aeap.2022.34.4.257. PMID: 35994578; PMCID: PMC9924357.
Overcoming COVID-19 disruptions: Innovations in product provision in a multi-national clinical trial among cisgender men, transgender men and transgender women in five countries.
Jacobson C, Johnson S, Billups T, Mitterer L, Chadza M, Gumede S, Manoyos V, Pareja K, Zemanek J, Jiao Y, Bauermeister J. Overcoming COVID-19 disruptions: Innovations in product provision in a multi-national clinical trial among cisgender men, transgender men and transgender women in five countries. Contemp Clin Trials Commun 2022 Aug;28:100930. PMCID: PMC9167802
Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.
Browne EN, Brown ER, Palanee-Phillips T, Reddy K, Naidoo L, Jeenarain N, Nair G, Husnik MJ, Singh D, Scheckter R, Soto-Torres L, Baeten JM, van der Straten A; MTN-020/ASPIRE Study Team. Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial. J Acquir Immune Defic Syndr 2022 Aug 1;90(4):418-424. PMCID: PMC9342948
Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial.
Roberts ST, Hawley I, Luecke E, Mensch B, Wagner T, Hoesley C, McClure T, Dominguez Islas CP, Piper JM, Liu AY, van der Straten A. Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial. J Womens Health (Larchmt) 2022 Jul;31(7):1029-1039. PMCID: PMC9299526
Impact of Dapivirine and Placebo Vaginal Rings on the Microbiota of Adolescent, Lactating, and Postmenopausal Females.
Austin MN, Meyn LA, Avolia HA, Petrina MA, Cosentino LA, Alphonse C, Chen BA, Bunge K, Noguchi L, Beigi R, Squires K, Hillier SL. Impact of Dapivirine and Placebo Vaginal Rings on the Microbiota of Adolescent, Lactating, and Postmenopausal Females. J Infect Dis 2022 Jun 15;225(12):2208-2218. PMCID: PMC9200158
Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention.
Reddy K, Mathebula F, Katz A, Luecke E, Tenza S, Palanee-Phillips T, Garcia M, Mansoor LE, Naidoo S, Morar N, Chitukuta M, Tsidya M, Montgomery ET; MTN-032 Study team. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention. AIDS Behav 2022 Jun;26(6):1923-1932. PMCID: PMC9050873
Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
Etima J, Katz AWK, Duby Z, Garcia M, Palanee-Phillips T, Reddy K, Mathebula F, Zimba C, Mansoor LE, Singh D, Manengamambo E, Naidoo S, Soto-Torres L, Montgomery ET; MTN-020/ASPIRE, MTN 025/HOPE, MTN-032 Study teams. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial. AIDS Behav 2022 May;26(5):1597-1606. PMCID: PMC9007827
Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026).
Bauermeister JA, Tingler RC, Dominguez C, Dunne EF, Hoesley C, Ho K, Johnson S, Lucas J, Macagna N, Brown E, Gundacker H, Peda M, Jacobson CE, Kramzer L, Singh D, Dezzutti CS, Ayudhya RPKN, Marzinke MA, Piper J, Devlin B, Nuttall J, McGowan I, Hendrix CW, Cranston RD; MTN 026 team. Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026). AIDS Behav 2022 May;26(5):1333-1346. PMCID: PMC9024063
Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials.
Hawley I, Song M, Scheckter R, McClure T, Piper J, Chen B, Hoesley C, Liu A, van der Straten A. Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials. AIDS Res Hum Retroviruses 2022 Apr;38(4):313-326. PMCID: PMC9048173